ArticleACS nano2021
Nanosac, a Noncationic and Soft Polyphenol Nanocapsule, Enables Systemic Delivery of siRNA to Solid Tumors.
Article in ACS nano, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 60 citations in OpenAlex.
- Tunable PEGylation platform for efficient siRNA delivery using mesoporous silica nanoparticles.Journal of biological engineering · 2026Article
- Small Interfering RNA Carriers for Oncotherapy: A Preclinical Overview.Pharmaceutics · 2025Review
- Mesoporous silica nanoparticle-based nanomedicine: Preparation, functional modification, and theranostic applications.Materials today. Bio · 2025Article
- Article
- Applications of liposomes and lipid nanoparticles in cancer therapy: current advances and prospects.Experimental hematology & oncology · 2025Review
- Nano drug delivery systems for advanced immune checkpoint blockade therapy.Theranostics · 2025Review
- DDX5 deficiency drives non-canonical NF-κB activation and NRF2 expression, influencing sorafenib response and hepatocellular carcinoma progression.Cell death & disease · 2024Article
- Combination of miR159 Mimics and Irinotecan Utilizing Lipid Nanoparticles for Enhanced Treatment of Colorectal Cancer.Pharmaceutics · 2024Article
- Recent trends in the delivery of RNA drugs: Beyond the liver, more than vaccine.European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 2024Review
- Tumour-microenvironment-responsive NaExploration (Beijing, China) · 2024Article
- Polydopamine nanomaterials and their potential applications in the treatment of autoimmune diseases.Drug delivery · 2023Review
- RNA helicase DDX5 modulates sorafenib sensitivity in hepatocellular carcinoma via the Wnt/β-catenin-ferroptosis axis.Cell death & disease · 2023Article
- Leveraging mesoporous silica nanomaterial for optimal immunotherapeutics against cancer.In vitro models · 2023Review
- Recent Advances in Mesoporous Silica Nanoparticles Delivering siRNA for Cancer Treatment.Pharmaceutics · 2023Review
- Nanomedicines: intervention in inflammatory pathways of cancer.Inflammopharmacology · 2023Review
- Oral polyphenol-armored nanomedicine for targeted modulation of gut microbiota-brain interactions in colitis.Science advances · 2023Article
- Mesoporous Silica Nanoparticles as a Gene Delivery Platform for Cancer Therapy.Pharmaceutics · 2023Review
- Targeted therapy for cisplatin-resistant lung cancer via aptamer-guided nano-zinc carriers containing USP14 siRNA.MedComm · 2023Article
- Combination therapy based on dual-target biomimetic nano-delivery system for overcoming cisplatin resistance in hepatocellular carcinoma.Journal of nanobiotechnology · 2023Article
- Protein corona: Friend or foe? Co-opting serum proteins for nanoparticle delivery.Advanced drug delivery reviews · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
For systemic delivery of small interfering RNA (siRNA) to solid tumors, the carrier must circulate avoiding premature degradation, extravasate and penetrate tumors, enter target cells, traffic to the intracellular destination, and release siRNA for gene silencing. However, existing siRNA carriers, which typically exhibit positive charges, fall short of these requirements by a large margin; thus, systemic delivery of siRNA to tumors remains a significant challenge. To overcome the limitations of existing approaches, we have developed a carrier of siRNA, called "Nanosac", a noncationic soft polyphenol nanocapsule. A siRNA-loaded Nanosac is produced by sequential coating of mesoporous silica nanoparticles (MSNs) with siRNA and polydopamine, followed by removal of the sacrificial MSN core. The Nanosac recruits serum albumin, co-opts caveolae-mediated endocytosis to enter tumor cells, and efficiently silences target genes. The softness of Nanosac improves extravasation and penetration into tumors compared to its hard counterpart. As a carrier of siRNA targeting PD-L1, Nanosac induces a significant attenuation of CT26 tumor growth by immune checkpoint blockade. These results support the utility of Nanosac in the systemic delivery of siRNA for solid tumor therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.